您当前所在的位置:首页 > 产品中心 > 产品详细信息
117976-89-3 分子结构
点击图片或这里关闭

2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole

ChemBase编号:1000
分子式:C18H21N3O3S
平均质量:359.44264
单一同位素质量:359.13036255
SMILES和InChIs

SMILES:
S(=O)(Cc1nccc(OCCCOC)c1C)c1[nH]c2c(n1)cccc2
Canonical SMILES:
COCCCOc1ccnc(c1C)CS(=O)c1nc2c([nH]1)cccc2
InChI:
InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
InChIKey:
YREYEVIYCVEVJK-UHFFFAOYSA-N

引用这个纪录

CBID:1000 http://www.chembase.cn/molecule-1000.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole
IUPAC传统名
rabeprazole
2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole
商标名
AcipHex
Pariet
别名
2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
Irsogladine Maleate
Rebeprazole sodium
rabeprazole sodium
Rabeprazole
CAS号
117976-89-3
MDL号
MFCD00868879
PubChem SID
160964463
46506366
PubChem CID
5029

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID 价格
上海毕得医药
BD16918 请登录

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 9.346711  质子受体
质子供体 LogD (pH = 5.5) 2.0682993 
LogD (pH = 7.4) 2.0861723  Log P 2.0907433 
摩尔折射率 98.0668 cm3 极化性 39.284637 Å3
极化表面积 77.1 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P 2.04  LOG S -3.03 
溶解度 3.36e-01 g/l 

分子性质

分子性质

理化性质 产品相关信息 生物活性(PubChem)
疏水性(logP)
0.6 expand 查看数据来源
纯度
95+% expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank
DrugBank -  DB01129 external link
Item Information
Drug Groups approved; investigational
Description Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Indication For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Pharmacology Rabeprazole prevents the production of acid in the stomach. It reduces symptoms and prevents injury to the esophagus or stomach in patients with gastroesophageal reflux disease (GERD) or ulcers. Rabeprazole is also useful in conditions that produce too much stomach acid such as Zollinger-Ellison syndrome. Rabeprazole may also be used with antibiotics to get rid of bacteria that are associated with some ulcers. Rabeprazole is a selective and irreversible proton pump inhibitor, suppresses gastric acid secretion by specific inhibition of the H+, K+ -ATPase, which is found at the secretory surface of parietal cells. In doing so, it inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic
Absorption Absolute bioavailability is approximately 52%.
Half Life 1-2 hours (in plasma)
Protein Binding 96.3% (bound to human plasma proteins)
Elimination Following a single 20 mg oral dose of 14C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites.
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
    暂无数据
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle